Insiders

GSK chief scientist Barron to leave for U.S. biotech start-up

January 19, 2022 at 03:32 am EST

LONDON (Reuters) - GlaxoSmithKline said on Wednesday that Hal Barron will end his position as chief scientific officer in August after less than five years to run a new privately owned start-up biotech company.

Tony Wood will become CSO designate and assume full accountability for Research and Development (R&D) on Aug. 1.

Barron will become a GSK non-executive director on Aug. 1, with additional responsibilities to support R&D, GSK said. He joined GSK in January 2018.

Barron is joining Altos Labs, a new biotech company based in San Francisco, California, focused on the biology of cellular rejuvenation programming with the goal of reversing disease, GSK said. (This story corrects first name to Hal, not Hall)

(Reporting by Josephine Mason; editing by Jason Neely)

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	MEGGITT PLC	798.8 GBX	-.--%	-.--%	7.35B

Hal Barron

Hal V. Barron occupies the position of Executive Director & Chief Scientific Officer at GlaxoSmithKline Plc. Dr. Barron is also on the board of GRAIL, Inc. and Cardiologist at UCSF Medical Center and Adjunct Professor at The University of California, San Francisco. Dr. Barron previously occupied the position of Director & Senior Vice President-Development at Arête Therapeutics, Inc., Chief Medical Officer & Executive Vice President at Roche & Genentech, Inc., President for Tesaro, Inc., Chief Medical Officer & EVP-Global Development at Genentech, Inc., Chief Medical Officer & Executive Vice President at F. Hoffmann-La Roche Ltd., Chief Medical Officer & Executive Vice President at Roche Pharmaceuticals, Inc. and President-Research & Development at Calico LLC. He received a doctorate from Yale University and an undergraduate degree from Washington University in St. Louis.

View full profile